[{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Novo Nordisk"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flagship Pioneering \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ GSK"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flagship Pioneering \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Pfizer Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Flagship Pioneering

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The collaboration aims to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 01, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The Flagship collaborates with GSK to discover and develop a portfolio of future transformational medicines and vaccines for the treatment of respiratory and immunology diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $150.0 million

                          July 29, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Discovery

                          Sponsor : GSK

                          Deal Size : $7,200.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery

                          Sponsor : Novo Nordisk

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Pioneering Medicines and the Cystic Fibrosis Foundation will partner with multiple companies within the Flagship ecosystem, leveraging emerging technologies including Tessera Therapeutics’ Gene WritingTM technology, targeted delivery modalities, and RN...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 11, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery

                          Sponsor : Cystic Fibrosis Foundation

                          Deal Size : $110.0 million

                          Deal Type : Partnership

                          blank